Robust recovery in non-COVID-19 business ensures a beat in Q1
04/05/21 -"Benefiting from strong demand for sample technology solutions and the QuantiFERON-TB test, Qiagen’s non-COVID-19 business was back in the black in Q1 21. Expectedly, COVID-19 products witnessed a ..."
Pages
64
Language
English
Published on
04/05/21
You may also be interested by these reports :
27/02/26
bioMerieux’s Q4 sales met expectations, with top-line growth driven by both segments. Management fulfilled its 2025 commitments and provided 2026 ...
25/02/26
Even though Q4 sales and profitability missed consensus, the markets seem happy with the 2026 outlook. Q4 performance was underpinned by healthy ...
25/02/26
Fresenius delivered solid Q4 25 results, supported by broad-based growth across Kabi and Helios. Biopharma remained the key growth engine, supported ...
24/02/26
FMC delivered a strong Q4 profit beat, with record profitability driven by accelerated FME25+ savings and operational discipline. FY 25 results also ...